CagriSema (Cagrilintide/Semaglutide)

Human clinical Weight Loss & Metabolism 2 sources

CagriSema is an investigational combination therapy containing cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist. Research shows this dual-action approach provides synergistic effects on appetite regulation, gastric emptying, and glucose metabolism, leading to greater weight loss and glycemic control than either compound alone.

01Dosing reference

Amount

Not applicable (Investigational GLP-1/Amylin combination)

Frequency

Not applicable

Cycle

Not applicable

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

Dual Receptor Activation

Semaglutide activates GLP-1 receptors while cagrilintide activates amylin and calcitonin receptors in the brain.

Synergistic Appetite Suppression

The combination delays gastric emptying and acts on different neural pathways to significantly reduce hunger and increase satiety.

Metabolic Optimization

This leads to profound reductions in body weight and improvements in HbA1c levels beyond what GLP-1 monotherapy achieves.

03Human evidence

Phase 2 trial in type 2 diabetes showed greater HbA1c reduction and weight loss with CagriSema compared to semaglutide or cagrilintide alone.

32-week randomized, double-blind trial in patients with type 2 diabetes.

Phase 2 trial in overweight/obesity demonstrated significant weight loss (15.6%) compared to semaglutide alone (5.1%).

20-week randomized trial in individuals without diabetes.

04Preclinical evidence

Co-administration of amylin and GLP-1 analogues showed synergistic reduction in food intake and body weight.

Diet-induced obese rat models; limited by species differences in receptor distribution.

Combination therapy improved insulin sensitivity and reduced hepatic steatosis more effectively than monotherapies.

Murine models of non-alcoholic fatty liver disease (NAFLD).

05What is known vs. unknown

Reasonably established

Combines a GLP-1 receptor agonist (semaglutide) with an amylin analogue (cagrilintide).
Demonstrates superior weight loss compared to semaglutide monotherapy in clinical trials.
Improves glycemic control in patients with type 2 diabetes.
Administered as a once-weekly subcutaneous injection.

Unknowns & limits

Long-term cardiovascular outcomes and safety profile are still being evaluated in ongoing Phase 3 trials.
Optimal dosing strategies and tolerability in broader populations require further study.
The exact contribution of calcitonin receptor activation by cagrilintide to the overall effect is not fully elucidated.

06Safety & regulatory context

Regulatory statusCagriSema is currently an investigational drug and is not yet FDA-approved. In clinical trials, the most common adverse events are gastrointestinal, including nausea, vomiting, and diarrhea, similar to other incretin-based therapies. The combination appears to have a safety profile consistent with its individual components. It is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

07Compared with Tirzepatide

CagriSema (Cagrilintide/Semaglutide) vs. Tirzepatide

Key difference

Tirzepatide is a dual GIP/GLP-1 receptor agonist, whereas CagriSema combines a GLP-1 agonist with an amylin analogue, targeting different pathways for appetite and metabolic regulation.

When researchers discuss each

Researchers discuss Tirzepatide when focusing on incretin co-agonism, while CagriSema is discussed when exploring the synergy between incretins and pancreatic islet hormones like amylin.

08Glossary

Amylin

A hormone co-secreted with insulin from the pancreas that helps regulate glucose and appetite.

GLP-1 Receptor Agonist

A class of medications that mimic the intestinal hormone GLP-1 to increase insulin secretion and reduce appetite.

Synergism

When two compounds work together to produce an effect greater than the sum of their individual effects.

09Knowledge check

Q1Which two hormones do the components of CagriSema mimic?

Q2What is the primary advantage of CagriSema over semaglutide monotherapy observed in clinical trials?

Q3Which documented limitation of the preclinical (animal) studies of the cagrilintide + semaglutide combination is explicitly mentioned in the dossier?

Q4According to the dossier, in which research context is CagriSema (cagrilintide/semaglutide) typically discussed compared with tirzepatide?

Q5Which safety or regulatory point about CagriSema is stated in the dossier?

10Sources

More in Weight Loss & Metabolism

See all

AOD-9604

Weight Loss & Metabolism

Human clinical

AOD-9604 is a modified fragment of human growth hormone (HGH) that includes amino acids 177-191. Research indicates it mimics the fat-burning effects of HGH by stimulating lipolysis and inhibiting lipogenesis, without the adverse effects on blood sugar or tissue growth typically associated with full-length HGH.

250-500 mcg/day

MOTS-c

Weight Loss & Metabolism

Early human

MOTS-c is a naturally occurring mitochondrial-derived peptide that plays a key role in regulating metabolic homeostasis and energy production. Research indicates it acts as an 'exercise mimetic' by activating AMPK, improving insulin sensitivity, and enhancing physical performance in animal models.

5-10 mg

GLP3-RT (Retatrutide)

Weight Loss & Metabolism

Human clinical

Retatrutide is an investigational triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors. Clinical trials have shown unprecedented weight loss efficacy, surpassing dual agonists, by combining appetite suppression with increased energy expenditure.

N/A - Investigational Drug

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.